Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Minerva Neuroscie (NERV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 308,628
  • Shares Outstanding, K 38,870
  • Annual Sales, $ 0 K
  • Annual Income, $ -31,520 K
  • 36-Month Beta 1.57
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.99

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.33
  • Number of Estimates 1
  • High Estimate -0.33
  • Low Estimate -0.33
  • Prior Year -0.24
  • Growth Rate Est. (year over year) -37.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.62 +2.76%
on 12/06/18
9.43 -16.97%
on 11/12/18
-1.72 (-18.01%)
since 11/09/18
3-Month
7.62 +2.76%
on 12/06/18
12.95 -39.54%
on 09/27/18
-1.92 (-19.69%)
since 09/10/18
52-Week
5.00 +56.60%
on 03/02/18
12.95 -39.54%
on 09/27/18
+2.13 (+37.37%)
since 12/08/17

Most Recent Stories

More News
Minerva Neurosciences Announces New Patent Application for MIN-117 Related to Broad Effect on Pain

WALTHAM, Mass., Nov. 28, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous...

NERV : 7.80 (-1.76%)
Minerva Neurosciences to Present at Evercore ISI HealthCONx Conference on November 28, 2018

WALTHAM, Mass., Nov. 21, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central...

NERV : 7.80 (-1.76%)
Minerva Neurosciences Announces Results of Dose Escalation Study Evaluating Roluperidone (MIN-101) Administered at Supra-Therapeutic Doses in Healthy Volunteers

- Findings suggest expanded therapeutic window and significantly improved cardiovascular safety margin compared to formulation used in Phase 2b trial

NERV : 7.80 (-1.76%)
Minerva Neurosciences Sees Hammer Chart Pattern: Time to Buy?

Minerva Neurosciences has been struggling lately, but the selling pressure may be coming to an end soon.

NERV : 7.80 (-1.76%)
Minerva Neurosciences to Host Roluperidone Update and Key Opinion Leader Discussion of Negative Symptoms in CNS/Psychiatric Diseases on November 20, 2018

Minerva management to provide update on Phase 3 clinical trial with roluperidone and single-dose escalation study findings

NERV : 7.80 (-1.76%)
New Research: Key Drivers of Growth for AxoGen, Spirit Realty Capital, e.l.f. Beauty, Minerva Neurosciences, Par Pacific, and Calithera Biosciences -- Factors of Influence, Major Initiatives and Sustained Production

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of AxoGen, Inc. (NASDAQ:AXGN),...

AXGN : 29.11 (-1.89%)
PARR : 16.29 (-3.50%)
SRC : 7.45 (-2.74%)
CALA : 4.83 (-1.43%)
ELF : 10.65 (-4.23%)
NERV : 7.80 (-1.76%)
Minerva Neurosciences to Present at Jefferies London Healthcare Conference on November 14, 2018

Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced...

NERV : 7.80 (-1.76%)
Minerva Neurosciences: 3Q Earnings Snapshot

WALTHAM, Mass. (AP) _ Minerva Neurosciences Inc. (NERV) on Monday reported a loss of $12 million in its third quarter.

NERV : 7.80 (-1.76%)
Minerva Neurosciences Reports Third Quarter 2018 Financial Results and Business Updates

Data readouts from five ongoing late-stage trials expected in 2019

NERV : 7.80 (-1.76%)
Minerva Neurosciences to Report Third Quarter 2018 Financial Results and Business Updates on November 5, 2018

Management to host conference call

NERV : 7.80 (-1.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade NERV with:

Business Summary

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The Company's pipeline will initially target the treatment of schizophrenia, major depressive...

See More

Key Turning Points

2nd Resistance Point 8.25
1st Resistance Point 8.10
Last Price 7.80
1st Support Level 7.78
2nd Support Level 7.61

See More

52-Week High 12.95
Fibonacci 61.8% 9.91
Fibonacci 50% 8.98
Fibonacci 38.2% 8.04
Last Price 7.80
52-Week Low 5.00

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar